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Background: Due to high prevalence of type 2 diabetes mellitus (T2DM) and increasing popularity of
bariatric and metabolic operations, Surgeons are faced with patients with relatively more severe T2DM
disease. High level of glycated hemoglobin (HbA1c) is widely considered as a marker for uncontrolled
T2DM. The aim of this study was to explore the correlation between high level of pre-operative HbA1c,
peri-operative morbidity and post operative outcome after laparoscopic sleeve gastrectomy.
Methods: We conducted a retrospective study based on our medical center metabolic and bariatric
registry. The inclusion criteria for selecting patients to the study group was HbA1c of 9 gram/dL and
higher. A comparison control study was designed to include T2DM patients similar in all characteristics
except for HbA1c of 7.5 gram/dl and less.
Results: We included 20 patients who underwent laparoscopic sleeve gastrectomy. Each group of pa-
tients included half of the patients. The mean pre operative HbA1c in the studied and the control group
were 10.4 gram/dL and 7.1 gram/dL respectively (p<0.001). There were no differences in peri-operative
morbidity and length of stay at the hospital. Mean excess weight loss, fasting glucose levels and HbA1c
levels were similar six months post surgery mean.
Conclusions: According to our study we have not found correlation between high HbA1c levels and
increased peri-operative morbidity or insufﬁcient excess weight loss among patients who underwent
laparoscopic sleeve gastrectomy.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Bariatric and metabolic surgery provides excess weight loss and
treatment of obesity related co-morbidities.1,2 Performing a bar-
iatric operation on a patient who suffers from Type two Diabetes
Mellitus (T2DM) is considered a highly effective procedure for
controlling glucose blood levels and improving T2DM.3 In fact,
currently this treatment resolves T2DM disease in up to 83% of the
patients.4 However, this effect correlates with the degree of the
disease. The remission rate of T2DM in patients who were diag-
nosed of T2DM 10 years or more prior to surgery is lower compare
to other patients.5 While, several articles were published regarding
the resolution of T2DM post-bariatric and metabolic surgery, theadassah-Hebrew University
rael. Tel.: þ972 2 6778800;
zary).
ciates Ltd. Published by Elsevier Ltperi-operative outcome of patients with T2DM has not been stud-
ied enough. The selection of which patient should not be operated
due to advanced or severe uncontrolled T2DM is based on specu-
lations and not by evidence basedmedicine. It is a commonpractice
among many surgical teams to exclude patients from surgical
treatment or at least to postpone further, scheduled operation due
to high level of glycated hemoglobin (HbA1c). The assumption that
patients with high HbA1c level are at greater risks of peri-operative
morbidity and mortality is probably extrapolated from peri-
operative outcome studies of non-bariatric procedures. However,
these risks are related to the presence of T2DM and not necessarily
to high levels of HbA1c which may play a role as a confounder.
Facing the growing population of T2DM patients and the strong
potential of bariatric and metabolic surgery in reversing the dis-
ease, these strategies and policies should be deduced from evi-
denced based studies. Therefore the aim of this study was to deﬁne
whether the peri-operative risk and the short term outcome of
T2DM patients allow performing sleeve gastrectomy in patients
with very high HbA1c levels.d. All rights reserved.
Table 2
Post-operative patients’ data.
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The study was conducted as a retrospective study. We achieved the Institutional
Review Board (IRB) approval for collecting and publishing data from the medical
center’s metabolic and bariatric registry. In this study, we included patients who
underwent laparoscopic sleeve gastrectomy between April 2011 and September
2012. Our medical center metabolic and bariatric surgery service’s policy is to
encourage patients together with their primary care physicians to control glucose
levels and improve T2DM prior to surgery. We recommend low carbohydrate and
high protein preoperative diet with a calorie restriction of 800 kcal per day and three
to ﬁve blood glucose measurements a day. Adjustments of oral anti diabetic medi-
cations or insulin injections are based on the patient’s primary care physician or
endocrinologist recommendations. Patients are re-evaluated at our clinic every two
weeks. We keep with this process for 2 months. However, we do not exclude patient
from operation if the patient has not lost weight unless we are convinced that efforts
to lose weight and to control T2DM disease have not been taken. We also do not
repeat blood test for Hb1Ac immediately prior to surgery. In this study we were
seeking for data of T2DM patients with HbA1c levels of 9 g/dL and higher. This cutoff
was quoted empirically due to: one, lack of deﬁnition of what extremely or very high
levels are and two, due to lack of studies with such elevated mean HbA1c levels. In
order to compare peri-operative morbidity, mortality and short term outcome, we
matched a control groupof T2DMpatientswhowas similar to the studied group in all
studied parameters except of HbA1c which was 7 g/dL and lower. The matched ele-
ments of both groups included: age, gender, body mass index (BMI) and years of
T2DM prior to surgery. Percentage of excess weight loss was calculated relative to
weight correlated with BMI of 25. Both groups were compared on the following
variables: major peri-operative complications, Length of hospital stay post-surgery,
re-admissions to the hospital in one month after the operation, percentage of excess
weight loss and change in HbA1c sixmonth post-surgery.We have not compared the
qualitative factors of number and types of anti diabeticmedications taken bypatients
due to our main aim of investigating the HbA1c quantitative variant. Due to small
sample size we applied non parametric statistical analysis methods. Continue vari-
ables were presented asmean standard deviation (SD) and the difference between
themwas deduced using the ManneWhitney U test. Categorical data was compared
using two tailed Fisher’s exact test. Statistical signiﬁcant difference was deﬁned by a
p-value of less than 0.01. The statistic power was calculated in order to assess sta-
tistically signiﬁcant differences due to relatively small number of patients included in
this study.
3. Results
Between April 2011 and September 2012 we performed 292
sleeve gastrectomy operations for treating obesity and its related
co-morbidity. Thirty seven of these patients were diagnosed to
suffer from T2DM disease. Out of this patients population we have
found 10 patients who met the study inclusion criteria and visited
the clinic 6 months following surgery with updated blood test re-
sults. We also matched a control group of patients which was
designed according to the study protocol (Table 1). The mean  SD
HbA1c levels of the studied and the control groups were
10.2  1and 7.1  0.5 respectively. The mean  SD fasting glucose
levels of the studied and the control groups were 218  73 and
128 23 respectively. Both differences were statistically signiﬁcant
(p< 0.001). The mean durations of T2DM disease in our study were
7.8  6.6 and 4.4  5.4 for the studied and the control groups (not
statistically signiﬁcant). Themean SD time elapsed from ﬁrst visit
to the clinic to the operation was 2.4  1.9 months. Comparing the
peri-operative course has shown that mean hospital length of stayTable 1
Preoperative patients’ characteristics.
High HbA1c
group
n ¼ 10
Control
group
n ¼ 10
Statistical
power
p
Gender (m/f) 3/7 4/6 0.7
Age, years 50.3  6.9 45.8  12.7 0.59
BMI, kg/m2 42.3  3.9 41.3  5.6 0.36
Years of T2DM 7.8  6.6 4.4  5.4 0.1
Fasting glucose,
mg/dL
218  73 128  23 0.96 <0.001
HbA1c, g/dL 10.4  1 7.1  0.5 1 <0.001was 4.7 and 5.2 days for the studied and for the control groups
respectively (not statistically signiﬁcant). In each group only one
patient was re-admitted, it was due to fever and mild deep wound
infection in the studied group and musculoskeletal pain not related
to surgery in the control group. There were no other major
complication including staple line leak.
Six months after the operation, mean excess weight loss in each
group was 63% and 56% among the studied and the control groups
respectively (not statistical signiﬁcant). Also, the differences in
parameters: BMI, fasting glucose and HbA1c level between the
groups were not statistically signiﬁcant. Not surprising, the mean
percentage change of HbA1c in each groupwere 36% and 16% in the
studied group and the control group respectively (p < 0.001).
The calculated statistical power of all parameters that was found
to be statistically signiﬁcant different was >0.76 (Tables 1 and 2).
4. Discussion
Treating patientswith uncontrolled T2DMbymetabolic operation
is very effective. Laparoscopic sleeve gastrectomy is one of several
procedures offered for treating morbid obesity and its related co-
morbidities.6 The popularity that sleeve gastric procedure gains
among surgeons is related to its simplicity and reproducibility. Its
mechanism includes major caloric restriction, however, improve-
ment of glucose control and T2DMbeforeweight loss occurs together
with human and animal experiments has raised several theories
regarding mechanisms far beyond food restriction only.7e9 The total
morbidity and major mortality rates of sleeve gastrectomy are fairly
the same as for gastric bypass. The most fearful surgical type of
morbidity is the gastric sleeve staple line leak which causes major
patient inconvenience.10 According to studies the average rate of leak
is less than 2.2%.11 Although it usually resolves without re-operation,
it heals very slowly and notoriously considered difﬁcult to treat.
In this study we included T2DM patients with very high HbA1c
levels. There is no consensus regarding not operating these pa-
tients. Searching the medical literature for articles describing
studies on the correlation between HbA1c levels and peri-operative
mortality and morbidity has shown controversy. Acott et al. pub-
lished a retrospective study of 2960 T2DM who underwent major
general surgery procedures.12 Their study showed higher rates of
peri-operative morbidity with no correlation to HbA1c levels. They
concluded that peri-operative complications among T2DM patients
may not be related to poor long term glucose control. Duckworth
et al. have studied the effect of intense glucose control of T2DM
patients with longstanding disease.13 The study included two
groups of patients, one was intensively treated for T2DM and the
second not. At the end of the study, the average HbA1c was 6.9 g%Post-operative course High HbA1c
group
n ¼ 10
Control
group
n ¼ 10
Statistical
power
p
Post-operative
complications
10% 0 0.7
Staple line leak 0 0 1
Post-operative length
of stay, days
4.7  0.9 5.2  2.5 0.87
Post-operative re-admission 10% 10% 1
Six months post-operation
BMI, kg/m2 31.7  4.1 32.3  4.7 0.91
Excess weight loss% 61  19 58  17 0.73
Fasting glucose, mg/dL 113  34 95  13.5 0.138
HbA1c, g/dL 6.8  0.8 6  0.5 0.76 0.01
Decrease in HbA1c% 36  9.3 16  8 0.99 <0.001
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(respectively). Also, they have not found any differences in rates of
cardiovascular events, death and microvascular disease (except for
microalbuminuria). On the other hand, as opposed to these studies,
Adler et al., performed meta-analysis which showed a linear asso-
ciation between levels of HbA1c and the risk of lower extremity
amputation in patients who suffers from T2DM.14
Interestingly, Rawlins et al. conducted a study of T2DM patients
who underwent laparoscopic Roux en Y gastric bypass.15 They set a
cutoff of 7 g/dL to select the patients to two groups. Themean HbA1c
level of patients in the high level group was 9 g/dL. They concluded
that patients with high HbA1c levels did not convey increased rate of
morbidity or mortality. Comparing our study methodology to this
study raises two major differences which we believe completes each
other: One,we included patientswho underwent sleeve gastrectomy
as opposed to patients underwent gastric bypass. Second, we studied
10 patients in each group compare to 170 patients at their study. This
size difference is a matter of an empiric decision related to cutoff
setting. From our point of view setting the cutoff as high as possible
and designing a control group of patientswhosemeanHbA1c level is
signiﬁcantly lower, potentiates our study conclusion that high HbA1c
levels do not correlate with high morbidity and mortality in patients
who underwent sleeve gastrectomy. Yip et al. conducted a study
which compares post-gastric bypass weight loss between morbidly
obese patients with and without T2DM.16 They concluded that the
presence of T2DM has not inﬂuenced the excess weight loss. In our
study we have not found any difference in weight loss related to the
level of HbA1c. Numerous reports have discussed the inﬂuence of
preoperative eating behavior on long term post-operative weight
loss. However, in T2DM the most important predicting factor for
short and long term post-operative T2DM improvement is the
duration of the disease and not the level of preoperative glucose
control. The mean duration of T2DM in our groups of patients was
not statistically signiﬁcant different but below ten years for both of
them. Probably similarity in diseases’ durations is a major determi-
nant of physiologic equal potential for reversing T2DM disease. It is
possible that if both groups would have included patients with
longer durations of disease the resultswould have been different.We
do believe that future studies should include large number of pa-
tients with long disease durations which will enable higher statis-
tical power, multi variance analysis and logistic regression in order to
study whether preoperative high HbA1c levels increases the post-
operative morbidity and mortality in patients with long duration of
T2DM disease.
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